RxDoctor Payments DataLook up a doctor →

Johnni Cansler, APRN

Psychiatric/Mental Health · Portland, ORNPI 1144709403

Payments from drug & device makers

$529,042in general payments, 2019–2025

Across 1,066 payments — averaging $496.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$468K
  • Axsome Therapeutics, Inc.$52K
  • Vanda Pharmaceuticals Inc.$6K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$632
  • Alkermes, Inc.$485
  • Otsuka America Pharmaceutical, Inc.$428
  • plus $1K from 10 others

What the payments were for

  • Consulting fees$31,6506%
  • Speaking & faculty fees$400,75576%
  • Travel & lodging$77,12315%
  • Food & beverage$19,4204%
  • Education$940%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$529,042 in reported general payments places this provider in the 95th percentile of 540 psychiatric/mental health providers in Oregon.

See all psychiatric/mental health providers in Oregon

Medicare billing

Part B allowed, 2024
$10,891
Medicare patients
19
Services billed
130

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate17$143,918
VraylarCariprazine Hcl91$128,685
AuvelityDextromethorphan Hbr/Bupropion74$82,427
CaplytaLumateperone Tosylate33$53,364
RexultiBrexpiprazole28$40,223
QelbreeViloxazine Hcl15$15,461
BelsomraSuvorexant12$5,066
Quetiapine Fumarate ErQuetiapine Fumarate23$4,958
Aripiprazole54$2,010
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine79$1,682
Gabapentin99$1,496
Vilazodone Hcl13$1,135
Prazosin Hcl41$1,031
Hydroxyzine Pamoate47$964
Hydroxyzine Hcl21$807

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$203$143,91817 claims
AbbVieVraylar$467,612$128,68591 claims
Axsome Therapeutics, Inc.Auvelity$52,187$82,42774 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$632$53,36433 claims
Otsuka America Pharmaceutical, Inc.Rexulti$428$40,22328 claims
Supernus Pharmaceuticals, Inc.Qelbree$21$15,46115 claims
MerckBelsomra$67$5,06612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 540 psychiatric/mental health providers in Oregon.

Other psychiatric/mental health in Portland

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →